BioMedNewsBreaks

FridayApr 24, 2026 2:57 pm

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment

LIXTE Biotechnology Holdings (NASDAQ: LIXT) is advancing the precision oncology landscape, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. “The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects,” reads a recent article. “By focusing on improving the therapeutic index of existing cancer modalities, the company is tackling a recurrent challenge in the field of oncology: maximizing treatment impact while cutting down risks to healthy tissue.” To view the full article, visit https://ibn.fm/EE6ya About LIXTE Biotechnology Holdings Inc. LIXTE…

Continue Reading

FridayApr 24, 2026 2:24 pm

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Advances Toward Commercial Deployment of AI Solution

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) was featured in a recent article that discussed its move toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a focus on industrial safety applications in South America’s mining sector. The publication reads, “The biotechnology company recently appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, a move that signals MindBio’s transition from technology development to field implementation in large enterprise environments… Leyton brings experience in national drug policy and…

Continue Reading

FridayApr 24, 2026 1:55 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Aligns with Next Phase of Telehealth Through Integrated Platform

Earth Science Tech (OTC: ETST) is positioned for opportunity as telehealth evolves from simple video visits into a comprehensive care model. “The company describes itself as a strategic holding company that acquires and actively manages operating businesses in pharmaceuticals, telemedicine, healthcare services, real estate, and selected consumer markets. ETST’s healthcare-related holdings include telemedicine and pharmaceutical operations designed to support a more connected platform approach; in addition, its compounding operations through RxCompoundStore.com and Mister Meds directly align with the expanding digital healthcare segment,” reads a recent article. “Earth Science Tech recently reported that its operations include compounding pharmaceuticals, telemedicine, and real estate…

Continue Reading

FridayApr 24, 2026 11:02 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on Pipeline-Driven Valuation 

Oncotelic Therapeutics (OTCQB: OTLC) is featured in a NetworkNewsAudio Audio Press Release titled “When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech,” which highlights how late-stage drug development assets increasingly drive valuation in the biopharma sector. The editorial, supported by analysis from McKinsey & Company, notes that companies tend to realize the majority of value creation as products approach commercialization, reflecting reduced risk and clearer revenue visibility, a trend directly relevant to Oncotelic’s oncology-focused pipeline and strategic development approach. To view the full press release, visit https://ibn.fm/0uj56 About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy…

Continue Reading

FridayApr 24, 2026 10:48 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Partnership Strategy to Advance Pipeline

Oncotelic Therapeutics (OTCQB: OTLC) provided a corporate update emphasizing its partnership-driven strategy to advance its oncology and rare disease pipeline and enhance shareholder value. The company cited its joint venture with GMP Biotechnology, which contributed to a $249.0 million increase in its balance sheet based on an independent third-party valuation, and said it is pursuing additional collaborations to support development and commercialization efforts. Management noted the approach is designed to advance multiple drug candidates in parallel while maintaining capital efficiency and unlocking the value of its intellectual property portfolio. To view the full press release, visit https://ibn.fm/gX9eb About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the…

Continue Reading

FridayApr 24, 2026 9:20 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces $2.61M Private Placement and Warrant Inducement 

Scinai Immunotherapeutics (NASDAQ: SCNI) announced it has entered into a securities purchase agreement with institutional and accredited investors for the sale of 5,208,333 ADSs at $0.48 per ADS, along with accompanying Series A and Series B warrants, and separately executed a warrant inducement agreement with an existing investor. The combined transactions are expected to generate approximately $2.61 million in gross proceeds, with closing anticipated on or about April 27, 2026, subject to customary conditions. The company said proceeds will support expansion of its CDMO platform, advancement of customer programs and continued investment in its immunotherapy pipeline. To view the full…

Continue Reading

ThursdayApr 23, 2026 12:33 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Collaborates to Advance Next-Gen ECG Solutions

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed its collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology. The publication indicates that the move, “highlights HeartBeam’s growing focus on artificial intelligence (‘AI’)-enabled analysis and reinforces the relevance of its technology as healthcare increasingly shifts toward data-driven, remote monitoring solutions. The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate high value, AI-based ECG algorithms that can be deployed broadly across HeartBeam’s platform. These AI models may include patient-relevant wellness insights, condition-focused assessments, and applications for chronic condition management.” To view the…

Continue Reading

ThursdayApr 23, 2026 11:24 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In BioMedWire Editorial On Biotech Valuation Shift 

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial examining how advancing drug pipelines are reshaping biotech valuations, as scientific progress is increasingly recognized as a measurable financial asset under evolving accounting frameworks. The piece highlights Oncotelic’s position at the intersection of oncology and AI-driven drug development, noting its diversified pipeline and strategic holdings, including a 45% stake in GMP Bio, as examples of how innovation and clinical advancement are being reflected in tangible enterprise value. To view the full press release, visit https://ibn.fm/JimL6 About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is…

Continue Reading

ThursdayApr 23, 2026 9:40 am

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Adds Robert Langer, Stephen Brannan To Scientific Advisory Board

This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its expertise in biotechnology, drug delivery and central nervous system clinical development as the company advances its pipeline of novel serotonergic agonists. The additions support Helus Pharma’s focus on disciplined, evidence-based drug development, including programs targeting major depressive disorder and generalized anxiety disorder, as it works to address unmet needs in mental health. To view the full press release, visit https://ibn.fm/CyjTq…

Continue Reading

ThursdayApr 23, 2026 9:30 am

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Preclinical Immuno-Oncology Data At AACR 2026

Tonix Pharmaceuticals (NASDAQ: TNXP) announced new preclinical data from its immuno-oncology portfolio, including TNX-1700 and TNX-4700, presented through one oral and two poster sessions at the American Association for Cancer Research Annual Meeting 2026 in San Diego. The company reported findings supporting TNX-1700’s potential in reducing inflammation and tumor progression in gastric cancer models and demonstrating favorable pharmacokinetics, while TNX-4700 showed promising in vitro activity targeting BTLA, underscoring its potential as a cancer immunotherapy candidate alone or in combination with other checkpoint inhibitors. To view the full press release, visit https://ibn.fm/Oly6o Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals is a fully-integrated,…

Continue Reading